147 related articles for article (PubMed ID: 37970190)
1. 5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population.
Deac AL; Pop RM; Burz CC; Bocşan IC; Militaru C; Suciu Ş; Buzoianu AD
Med Pharm Rep; 2023 Oct; 96(4):413-419. PubMed ID: 37970190
[TBL] [Abstract][Full Text] [Related]
2. Correlation between pharmacokinetic parameters of 5-fluorouracil and related metabolites and adverse reactions in East-Asian patients with advanced colorectal cancer.
Tong Z; Cheng M; Yu Y; Yu J; Yin Y; Liu J; Zhang S; Jiang S; Dong M
Cancer Chemother Pharmacol; 2022 Mar; 89(3):323-330. PubMed ID: 35067736
[TBL] [Abstract][Full Text] [Related]
3. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
4. Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy.
Zhou X; Chang Y; Qian J; Shen C; Han J; Zhao H; Chang R
Med Sci Monit; 2021 Jul; 27():e929474. PubMed ID: 34330885
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
6. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer.
Yang Q; Bi Y; Li X; Liu Q; Ma J; Zhang C; Zhang J; He G
Eur J Hosp Pharm; 2020 Mar; 27(e1):e36-e40. PubMed ID: 32296503
[TBL] [Abstract][Full Text] [Related]
8. The Incidence of Hematological Toxicities in Colorectal Cancer Patients Treated With Fluoropyrimidine-Based Regimens at Princess Noorah Oncology Center.
Khan M; Alharbi S; Aljuhani S; Tunkar M; Morya A; Alnatsheh A; Alshamrani M; Felemban R
Cureus; 2023 Aug; 15(8):e44267. PubMed ID: 37772227
[TBL] [Abstract][Full Text] [Related]
9. Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.
Wilhelm M; Mueller L; Miller MC; Link K; Holdenrieder S; Bertsch T; Kunzmann V; Stoetzer OJ; Suttmann I; Braess J; Birkmann J; Roessler M; Moritz B; Kraff S; Salamone SJ; Jaehde U
Clin Colorectal Cancer; 2016 Dec; 15(4):381-388. PubMed ID: 27256667
[TBL] [Abstract][Full Text] [Related]
10. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
11. Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study.
Li M; Mindt S; Lück A; Hutzschenreuter U; Kollendt M; Lathan B; Zöller T; Frank-Gleich S; Lorentz C; Lamberti C; Sick C; Zingerle M; Tesch H; Stein W; Hebart H; Stosiek C; Sandner R; Fries S; Burkholder I; Hofheinz RD
ESMO Open; 2023 Apr; 8(2):101201. PubMed ID: 36965262
[TBL] [Abstract][Full Text] [Related]
12. A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity.
Esin E; Telli TA; Yuce D; Yalcin S
Tumori; 2018 Jun; 104(3):157-164. PubMed ID: 28708227
[TBL] [Abstract][Full Text] [Related]
13. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
[TBL] [Abstract][Full Text] [Related]
15. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion.
Grem JL; Quinn M; Ismail AS; Takimoto CH; Lush R; Liewehr DJ; Steinberg SM; Balis FM; Chen AP; Monahan BP; Harold N; Corse W; Pang J; Murphy RF; Allegra CJ; Hamilton JM
Cancer Chemother Pharmacol; 2001; 47(2):117-25. PubMed ID: 11269737
[TBL] [Abstract][Full Text] [Related]
17. Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients.
Fang L; Jiang Y; Yang Y; Zheng Y; Zheng J; Jiang H; Zhang S; Lin L; Zheng J; Zhang S; Zhuang X
Oncotarget; 2016 Dec; 7(49):81880-81887. PubMed ID: 27636992
[TBL] [Abstract][Full Text] [Related]
18. Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion.
Freeman K; Connock M; Cummins E; Gurung T; Taylor-Phillips S; Court R; Saunders M; Clarke A; Sutcliffe P
Health Technol Assess; 2015 Nov; 19(91):1-321, v-vi. PubMed ID: 26542268
[TBL] [Abstract][Full Text] [Related]
19. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.
Hamzic S; Aebi S; Joerger M; Montemurro M; Ansari M; Amstutz U; Largiadèr C
Swiss Med Wkly; 2020 Nov; 150():w20375. PubMed ID: 33232506
[TBL] [Abstract][Full Text] [Related]
20. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
